AIDSWEEKLY Plus; Monday, October 17, 2005
Staff Medical Writers

According to a recent review from the United States, "The immune system faces the difficult task of discerning between foreign, potentially pathogen-derived antigens and self-antigens.

"Several mechanisms, including deletion of self-reactive T cells in the thymus, have been shown to contribute to the acceptance of self-antigens and the reciprocal reactivity to foreign antigens."

"Over the last decade it has become increasingly clear that CD4+CD25+ T-Reg cells are crucial for maintenance of T cell tolerance to self-antigens in the periphery and to avoid development of autoimmune disorders.

"Recently, evidence has also emerged that demonstrates that CD4+CD25+ T-Reg cells can also suppress T cell responses to foreign pathogens, including viruses such as HIV," wrote D.F. Nixon and colleagues at the University of California, San Francisco.

"In this article, we review the current knowledge and potential role of CD4+CD25+ T-Reg cells in HIV infection," the authors concluded.

Nixon and colleagues published their study in Microbes and Infection (CD4+CD25+ regulatory T cells in HIV infection. Microbes Infect. 2005 Jun;7(7-8):1063-5.

For additional information, contact D.F. Nixon, University of California San Francisco, Gladstone Institute, Gladstone Institute Virology & Immunology, 1650 Owens St., San Francisco, CA 94158, USA.

Publisher contact information for the journal Microbes and Infection is: Elsevier Science BV, PO Box 211, 1000 AE Amsterdam, Netherlands.

Keywords: San Francisco, California, United States, HIV/AIDS, Autoimmune Disorders, CD4+CD25+ Regulatory T Cells, T Cell Tolerance.

This article was prepared by AIDS Weekly editors from staff and other reports.

Reference

Nixon DF, Aandahl EM, Michaelsson J. CD4+CD25+ regulatory T cells in HIV infection, Microbes Infect. 2005 Jun;7(7-8):1063-5.

PubMED Related articles Search

051017
AW051009

Copyright © 2005 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone/Firestone Charitable Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright © 1980,2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.